Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-4480

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-4480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Oxcarbazepine 150mg 70518 4480 01)

Oxcarbazepine 150 mg tablet label showing a single film-coated tablet. The label includes product NDC 70518-4480-01 and indicates repackaging by RemedyRepack Inc. in Indiana, PA. The tablet is described as oval and brown, with storage instructions and a reminder that it is prescription only (RX ONLY).*

FDA Label Image

Remedy_label (Remedy Label)

Oxcarbazepine 150 mg film-coated tablets packaging label indicating a box quantity of 100 tablets. The oval brown tablets are identified with code B292. Label notes the product is repackaged by RemedyRepack Inc., Indiana, PA, and includes storage instructions and a lot number section. The label highlights prescription use only and references usual dosage information in the insert.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, showing its bicyclic framework with a ketone group and amide substitution.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier plot showing exit rate over time in days from Day 2 to Day 11 at 8 am, comparing treatment groups Oxcarbazepine and Placebo. The solid line represents Oxcarbazepine, showing a lower exit rate, while the dotted line represents Placebo with a higher exit rate. The graph includes a log-rank test p-value of 0.0001, indicating a statistical comparison between groups.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve displaying seizure rate over 140 days from first dose to first seizure. It compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line), with a log-rank test p-value of 0.046 indicating a statistical comparison between groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A line chart depicting exit rate over time in days for two treatment groups labeled HIGH and LOW. The exit rate increases over time, with the LOW group showing a steeper and earlier rise compared to the HIGH group. The chart includes a log-rank test p-value of 0.0001, indicating statistical comparison between the groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier curve chart showing exit rate over time in days for two treatment groups labeled 'HIGH' and 'LOW'. The chart includes a log-rank test p-value of 0.0001, indicating a significant difference between the groups. The x-axis represents time to exit (days), and the y-axis represents the exit rate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.